Validation of the Snouda Metabolic Score for Phenotyping and Guiding Reversal in Type 2 Diabetes
Key facts
- Where
- Manchester, United KingdomSee the site
Where in United Kingdom
- Snouda Health Coaching LtdManchester, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Salah Snouda
- Trial code
- NCT07606872
- Record updated
- 18 August 2026
- Original description
This study tests a new tool called the Snouda Metabolic Score (SMS) that helps doctors identify the specific metabolic problems driving Type 2 Diabetes in each individual patient. Instead of treating all diabetic patients the same way, the SMS classifies patients into one of several metabolic phenotypes - patterns of dysfunction across five body systems: insulin resistance, chronic inflammation, hormonal disruption, gut microbiome imbalance, and mitochondrial dysfunction.Read full original descriptionShow less
A Prospective Interventional Clinical Validation Study of the Snouda Metabolic Score (SMS) as a Phenotyping and Protocol-Targeting Instrument in Adults With Type 2 Diabetes Mellitus
This study tests a new tool called the Snouda Metabolic Score (SMS) that helps doctors identify the specific metabolic problems driving Type 2 Diabetes in each individual patient. Instead of treating all diabetic patients the same way, the SMS classifies patients into one of several metabolic phenotypes - patterns of dysfunction across five body systems: insulin resistance, chronic inflammation, hormonal disruption, gut microbiome imbalance, and mitochondrial dysfunction.
Once classified, each participant follows a personalized 24-week lifestyle and nutritional protocol targeting their specific phenotype. The protocol includes dietary changes, structured exercise, targeted nutritional supplements, and optional intermittent fasting. Participants track their blood glucose daily and complete biomarker blood tests at the start and end of the study.
The main goal is to determine whether the SMS tool accurately identifies metabolic phenotypes and whether phenotype-matched protocols produce better outcomes than standard approaches. The study measures changes in HbA1c, fasting insulin, C-peptide, inflammation markers, and whether participants achieve Type 2 Diabetes remission - defined as HbA1c below 6.5% without glucose-lowering medication.
The study is conducted entirely online through the diabetesreversal.io platform. There are no clinic visits required. Participants must be adults aged 18 or older with a confirmed Type 2 Diabetes diagnosis and must not be pregnant or breastfeeding.
Inclusion: Confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) by a licensed healthcare provider; Age 18 years or older; HbA1c between 6.5% and 11.0% at baseline; Currently managed with lifestyle measures alone, or with oral glucose-lowering medications (metformin, SGLT2 inhibitors, DPP-4 inhibitors, or sulfonylureas); Ability to access and use the diabetesreversal.io digital platform; Willingness to perform daily self-monitoring of blood glucose; Willingness to complete laboratory blood tests (Genesis Biomarker Panel) at baseline and Week 24 at own expense; Able to provide written informed consent.
Exclusion: Currently using insulin therapy; Currently using GLP-1 receptor agonists (e.g., semaglutide, liraglutide); Active malignancy or receiving chemotherapy or radiation therapy; Type 1 Diabetes Mellitus or Latent Autoimmune Diabetes in Adults (LADA); History of severe hypoglycemia requiring third-party assistance in the past 12 months; Severe hepatic impairment; Active eating disorder; Any condition that in the opinion of the investigator would make participation unsafe or interfere with study completion; HbA1c greater than 11.0% at baseline; Severe renal impairment (eGFR less than 30 mL/min/1.73m²); Currently pregnant or breastfeeding.